Jane Brandman

We have been keeping a close eye on emerging data that describe the implications of climate change on diseases in our research portfolio. An increasing pool of modeling studies indicate that changes are likely in the epidemiology of certain vector-borne (e.g., malaria and dengue) and water-borne (e.g., cryptosporidiosis diarrhea) diseases because of rising global temperatures. Specifically, evidence suggests these conditions could be exacerbated in regions where they are already endemic and could spread to new areas. There is also concern that the effects could more severely impact populations in low- and middle-income countries depending on the resiliency of civic and health infrastructures. For these reasons and more we have worked with the Financial Times to review state-of-the-art knowledge on this topic. Please learn more at the links below!

62

2 Comments

"IQVIA estimates that the dearth of a Humira (adalimumab) biosimilars last year cost patients and employers cumulatively $6 billion." #Biosimilars #Adalimumab like #Hulio from #BioconBiologics can provide #affordable #access to #patients and save billions for the Government. #Biosimilars are the way forward for affordable biologics therapy. Read the article: US Specific "The biosimilar Hulio was offered last year at a WAC of $498 for a month's supply, versus $3,461 for Humira, according to a Samsung Bioepis biosimilar report. Still, the vast majority of prescriptions filled in 2023 were for the Humira originator product, prompting market research group IQVIA to conclude that “maintaining patients on Humira comes at a cost of up to about $6 billion per year for patients and employers, compared to a full transition to adalimumab biosimilars.” Biocon Biologics Matt Erick Joshua Salsi https://lnkd.in/gN74FShF

33

In our New Medicines, Novel Insights Oncology report, Dr. Gwyn Bebb reflects on the paradoxes and challenges we encounter while striving to make precision oncology a reality and his vision for the future. Hear from Dr. Bebb on the complexities of treating each patient with the exact right medicine ─ and why we must realize the vision: https://lnkd.in/geYT8fup #ParexelBiotech #CancerResearch #Oncology #NovelInsights

2

🎙️ Tune in to our Advancing Precision Oncology Podcast! This 3-part series will explore how biomarkers and advanced testing capabilities are expanding patient access to precision oncology and improving health outcomes for cancer patients. Delve into the rapidly evolving landscape of biomarker testing, the benefits of integrating multi-data sources and the challenges and opportunities that lie ahead. 🔬💊 Listen to Part 1 with Dr. Gwyn Bebb and Wyatt Gotbetter: https://lnkd.in/gdC7SxDf #ParexelBiotech #Oncology #Biomarkers #NovelInsights

3

This post is intended for a U.S. audience.    AstraZeneca is making real progress in redefining cancer care. The data we’ll be sharing at the upcoming #ASCO24 Annual Meeting includes back-to-back plenary presentations from early #LungCancer settings – evidence of our work toward moving treatment into earlier-stage disease, when patients have the best chance for improving outcomes. This is the sixth year in a row AZ data are featured in the meeting’s premier session.     Meeting data also include important metastatic #BreastCancer results, where we continue to redefine the treatment landscape. Other data in lung, breast, gastrointestinal, gynecological, and a number of pan-tumor studies, will be presented as well.    I’m looking forward to meeting up with the oncology community to share our findings and discuss the future of cancer medicine, and I hope we get the chance to talk.    For a full preview of our #ASCO24 data presentations, see our press release.    #USOnly #AstraZenecaUS 

98

Shortly after joining Celgene in 2011, we lost Apple Co-Founder Steve Jobs after his long battle with pancreatic cancer. This event coincided with the anticipation surrounding Abraxane's pancreatic data readout. The results were significant: in patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine notably improved overall survival (OS), progression-free survival (PFS), and response rate (ORR), despite increased rates of peripheral neuropathy and myelosuppression. Abraxane + gemcitabine was eventually approved for the treatment of metastatic pancreatic cancer as part of the FDA's Priority Review program which was a huge victory in the war against pancreatic cancer, one of the deadliest cancers if discovered once it has spread to the rest of the body (metastatic). Steve Jobs, a captivating figure, left a lasting legacy through Apple, Pixar Animation Studios, and his four children. While known for his technological influence, his battle with pancreatic cancer added significant depth to his story for me personally. For those intrigued by his journey, Walter Isaacson’s biography offers a comprehensive exploration: https://lnkd.in/eAm4dWtj) In light of Jobs' story, I advocate for supporting pancreatic cancer research and patient care. Consider contributing to organizations like The Lustgarten Foundation and the Pancreatic Cancer Action Network, vital in advancing treatment options and improving outcomes for those affected by this challenging disease. As someone passionate about giving back, I encourage donations to these causes in honor of loved ones, like my Uncle Earl. Together, we can make a difference in the fight against pancreatic cancer and support ongoing advancements in oncology. I learned a lot from folks like Craig Phillips, Michele Korfin, Shubh G., Steve Gavel, Michael Amoroso, Alex Cavin, Filip Odqvist, Kevin Manning, and many others. I'm tagging them in this post - I can't believe how long it's been since we all worked on such an important launch. I hope to see you all at ESMO in Barcelona this September! #PancreaticCancer #OncologyResearch #CharityDonations #LustgartenFoundation #PancreaticCancerActionNetwork #SteveJobsLegacy

27

6 Comments

Looking for how to have courteous discussions with friends and family when politically at odds? This episode can help. Really. How to Win Thanksgiving on Cancer in the Form of a Question. Check it out!

5

AbbVie today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY® (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody administered subcutaneously for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of prior therapy. This indication is approved under the FDA's Accelerated Approval program based on overall response rate (ORR) and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). "The FDA approval of EPKINLY offers a new treatment option for relapsed or refractory follicular lymphoma, particularly following failure of other therapies," said Mariana Cota Stirner, M.D., Ph.D., vice president, therapeutic area head for hematology, AbbVie. "EPKINLY treatment has shown deep and durable responses for many patients. Subcutaneous dosing offers convenience, and EPKINLY can be given to patients without mandatory hospitalization using a 3-step-up dosing regimen. We believe that EPKINLY has the potential to be a core therapy in the treatment of multiple B-cell malignancies and furthers our company mission to advance research to raise standards of care for patients with cancer." Epcoritamab is being co-developed by AbbVie and Genmab as part of the companies' oncology collaboration. The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. FL is typically an indolent (or slow-growing) form of non-Hodgkin's lymphoma (NHL) that arises from B-lymphocytes and is the second most common form of NHL accounting for 20-30% of all cases. About 15,000 people develop FL each year in the U.S.3 and it is considered incurable with current standard of care therapies. Patients often relapse and, with each relapse the remission and time to next treatment is shorter. "Patients with relapsed or refractory follicular lymphoma face significant treatment challenges, and there is currently no clear standard of care treatment available across practice settings," said Jeff Sharman M.D., Disease Chair, Hematology Research, Sarah Cannon Research Institute (SCRI) at Willamette Valley Cancer Institute in Eugene, Oregon. "The responses observed in the follicular lymphoma cohort of the EPCORE NHL-1 clinical trial, as well as in patients with relapsed or refractory DLBCL from the trial, show the potential of EPKINLY to serve as an important treatment option for these patients." "People living with follicular lymphoma are in need of additional options when their cancer returns," said Lee Greenberger, Ph.D., Chief Scientific Officer at The Leukemia & Lymphoma Society. "Today's approval is welcome news for patients, as it provides another tool in the physician arsenal for this difficult-to-treat form of cancer." #hematology #oncology #follicularlymphoma  #epcoritamab #EPKINLY #AbbVie #Genmab

104

Front row seats for Teva Pharmaceuticals friends and colleagues tuning in for #QuarterlyResults! We are off to a strong start in 2024 as we mark the one-year anniversary of launching our #PivotToGrowth strategy. Personally, I am especially proud of my Teva R&D team who are uber-focused delivering advancements in our innovative pipeline while also showing how we at Teva are #GenericsInnovators, too! The most exciting news for me today are the positive Phase 3 results from our SOLARIS trial evaluating efficacy of a long-acting treatment option for schizophrenia, which brings us closer to our goal to deliver another innovative treatment option for the millions of people with schizophrenia. We are dedicated to pursuing new scientific innovations to meet the needs of the schizophrenia community and it’s our hope that we can advance the science to help reduce the burden of the condition for these patients, their caregivers and loved ones. The SOLARIS/Olanzapine Phase 3 efficacy data news is here: https://lnkd.in/eTCvt-C7 Read more about Teva’s Q1 performance here: https://lnkd.in/eAc8DnD3 More to come - watch this space! #TogetherWeCanHelpPatients #TevaPharm #InnovativeMedicines #TevaRnDThePlaceToBe #PivottoGrowth #Earnings 

716

16 Comments

May is #BladderCancerAwarenessMonth, a time to shine a light on a disease that affects thousands of individuals and their families. Bladder cancer is a significant health concern, with over 80,000 estimated diagnoses in the U.S. this year alone. Early detection is key, as it greatly improves patient outcomes. Let's educate ourselves on the signs and symptoms of bladder cancer by visiting the informative resources available on BCAN's website. Together, we can make a difference and support #BladderCancerAwarenessMonth. Learn more here: https://lnkd.in/eV_rybCy

73

2 Comments

The Abbvie vs Sanofi/Regeneron battle for Eczema is HOT - WHY? Here´s my take on the latest results of the last trial of Rinvoq vs Dupixent Also, I´m an eczema patient.... 1 - Rinvoq Clinically Superior (For Now): In the LEVEL UP trial, Rinvoq achieved near-complete skin clearance (with little to no itch) in 20% of patients with moderate-to-severe eczema after 16 weeks, compared to only 9% on Dupixent. This translates to a potentially significant improvement for patients. It's worth noting that this is the second time in four years #Rinvoq has bested Dupixent in head-to-head trials. 2 - Eczema Market Up for Grabs (With Data to Back It Up): Dupixent currently holds the dominant position in the eczema market, generating a whopping $11.6 billion in sales for 2023. However, Rinvoq's impressive results, especially considering it aced all secondary objectives in the trial, could lead to a significant shift. The key will be translating these trial results into real-world effectiveness and physician adoption. 3 - AbbVie's Strategy Validated (But Not Risk-Free): Rinvoq's success is a major win for AbbVie's strategy of diversifying its immunology portfolio beyond Humira's patent expiry. This cements their position as a key player in the lucrative eczema market, estimated to be worth over $15 billion by 2025. However, competition is fierce, and Dupixent still holds the upper hand in terms of broader age group approval (6 months and older vs. 12 and older for Rinvoq). 4 - Safety Concerns Mitigated (For Now): The previous safety concerns surrounding Rinvoq, which overshadowed their 2020 win, seem to be addressed in this trial. The researchers used a lower starting dose (15mg) with adjustments up to 30mg, and no new safety signals were identified. However, long-term safety data is still crucial, and investors should monitor any future developments. 5 - Dupixent Still a Formidable Foe, But Vulnerable: Let's not count Dupixent out. It boasts a broader age range approval and is on the cusp of potentially blockbuster sales in COPD (chronic obstructive pulmonary disease). Analyst projections estimate Dupixent's sales could reach over $20 billion by 2030. However, investors should be aware of the growing threat Rinvoq poses, especially if AbbVie can translate trial success into real-world results. What do you think about how the Eczema market will move after that? Leave a comment below Happy to answer any specific questions you may have about the biotech investment landscape #biotech #investment #investor #vc #drug #discovery #healthcare #market #business #patient #eczema _________________________________________________________________________________ Biotech investor or innovator? We assist investors unlock potential by assisting with due diligence and companies refine strategies for success and fundraising. Let's chat! Have you enjoyed this? Recommend Repost ♻️ if you find it useful Follow me, hit the 🔔 Adrian Rubstein

15

Grace Leadership is about inspiring belief in others and turning that belief into reality, which requires grace. The poise of a dancer, the fluid motion of an athlete—true Grace is revealed under pressure, sometimes even fire. Grace is the humble voice that reminds us, "It's not about you." It beckons us toward accountability, responsibility, and action. Indeed, the accountability we seek in others begins with ourselves. When challenges arise and the path ahead is uncertain, grit drives us forward. It's the relentless determination that fortifies us against all odds. Yet, leading others demands more than just grit. Grit answers to grace—the true ruler. In failure, grace reassures us that we will be more than okay—we will improve. In success, grace protects us from arrogance. What matters is our conduct, the legacy we create, and the feelings we evoke in others—our grace. Consider moments of crisis. People observe who panics and who remains composed. They invariably focus on the individual radiating the confidence that 'everything will be okay.' With this in mind, we must contemplate: Are we the ones people look to? Regardless of circumstances, do we possess the grit to remain graceful? Reflecting separately, I recognize that Grace is also a name! My Sunday morning reflections, inspired by my journey and Gary Burnison Book.

183

8 Comments

From companion diagnostics to patient molecular profiles, AbbVie scientists are making big bets to propel #immunology research to its next frontier. See how their work aims to reimagine the standards of care for patients with autoimmune diseases like #IBD #WeAreAbbVie

10

Announcing Our "New Medicines, Novel Insights" Report: Revolutionizing Cancer Care I am thrilled to share our "New Medicines, Novel Insights" report, a significant step toward realizing the full potential of precision oncology. While many patients still face barriers to these life-changing treatments, our report offers hope and actionable strategies for better outcomes. Inside, you'll find: -Survivor Stories: Inspiring experiences with precision treatments. -Expert Insights: On clinical trials, regulatory strategies, and market access. -Actionable Steps: To accelerate precision cancer medicines to market. Join me in revolutionizing cancer care. Read the report here: Parexel #InternationalClinicalTrialsDay #CancerCare #Parexel #Withheart #Mycompany #Clinicaltrials #Oncology #PrecisionOncology #Puttingpatientsfirst

93

2 Comments

#News: Even through an onslaught of #biosimilar launches that began early last year, AbbVie’s big-selling #Humira has been able to retain most of its lucrative market. Still, though, the drug’s star power is on the decline. Biosimilar manufacturer Samsung Bioepis has tracked the impact of Humira biosim launches in its latest market report, finding that Humira’s slice of the market has dropped to 82%. Sandoz’ #Hyrimoz, under its #Cordavis co-label, is responsible for “most biosimilar gains,” according to the report. Cordavis is CVS Health’s new biosimilar subsidiary, which launched with Hyrimoz as its first product. Read more from Fierce Pharma 👇🏼

4

#News: Due to Bristol Myers Squibb’s portfolio prioritization efforts, Eisai US is taking back an #antibodydrugconjugate that they originally teamed up on in 2021. #Eisai will now develop and commercialize the #ADC alone, known as farletuzumab ecteribulin (FZEC). It’s a combination of a folate receptor antibody (FRα) and the chemotherapy Halaven. In the original deal announced in June 2021, Bristol Myers paid $650 million, with $200 million of that toward Eisai’s R&D efforts for shared global rights. The deal included up to $2.45 billion in future milestones and royalties, and the companies planned to jointly develop and sell the drug in the US, EU, UK, Russia, Japan, China and other Asia-Pacific countries. Now, Eisai will also hand back a part of the original $200 million R&D payment that it hasn’t used yet. Eisai said in a Monday announcement that it considered the ADC a “high priority” and would accelerate its development “with the hope to deliver it to patients as early as possible.” Read more from Endpoints News 👇🏽 https://lnkd.in/e8FSRgF2

2

Driven by a unified purpose to impact the lives of people living with advanced cancers, Novartis is working to create a future where every eligible patient can receive radioligand therapies (RLTs) not just today—but into the future.   Learn more about this commitment to RLT: https://lnkd.in/g8JcTs7A   #ASCO24 #NovartisTogether

72